Jiangsu NHWA Pharma announced that DP-VPA, its in-licensed epilepsy treatment, was granted Fast Track designation by the CFDA. DP-VPA combines a well-known generic drug for epilepsy, valproic acid (VPA), with a lipid coating to minimize side effects. In 2011, NHWA acquired exclusive China rights (including Hong Kong and Macau) to DP-VPA from D-Pharm, an Israeli biopharma.
Help employers find you! Check out all the jobs and post your resume.
